IDH1 and glioma: In terms of EGFR amplification and TERT promoter mutation, our findings confirm published results: Jaunmuktane et al. found that 82.88% of IDH and TERT wildtype gliomas were EGFR non-amplified, while only 17.12% were EGFR amplified.